Characterization of structure and function of ZS-9, a K+ selective ion trap

Hyperkalemia, a condition in which serum potassium ions (K+) exceed 5.0 mmol/L, is a common electrolyte disorder associated with substantial morbidity. Current methods of managing hyperkalemia, including organic polymer resins such as sodium polystyrene sulfonate (SPS), are poorly tolerated and/or n...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 9; no. 12; p. e114686
Main Authors Stavros, Fiona, Yang, Alex, Leon, Alejandro, Nuttall, Mark, Rasmussen, Henrik S
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 22.12.2014
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Hyperkalemia, a condition in which serum potassium ions (K+) exceed 5.0 mmol/L, is a common electrolyte disorder associated with substantial morbidity. Current methods of managing hyperkalemia, including organic polymer resins such as sodium polystyrene sulfonate (SPS), are poorly tolerated and/or not effective. Sodium zirconium cyclosilicate (ZS-9) is under clinical development as an orally administered, non-absorbed, novel, inorganic microporous zirconium silicate compound that selectively removes excess K+ in vivo. The development, structure and ion exchange properties of ZS-9 and its hypothesized mechanism of action are described. Based on calculation of the interatomic distances between the atoms forming the ZS-9 micropores, the size of the pore opening was determined to be ∼ 3 Å (∼ diameter of unhydrated K+). Unlike nonspecific organic polymer resins like SPS, the ZS-9 K+ exchange capacity (KEC) was unaffected by the presence of calcium (Ca2+) or magnesium ions (Mg2+) and showed>25-fold selectivity for K+ over either Ca2+ or Mg2+. Conversely, the selectivity of SPS for K+ was only 0.2-0.3 times its selectivity for Ca2+ or Mg2+in mixed ionic media. It is hypothesized that the high K+ specificity of ZS-9 is attributable to the chemical composition and diameter of the micropores, which possibly act in an analogous manner to the selectivity filter utilized by physiologic K+ channels. This hypothesized mechanism of action is supported by the multi-ion exchange studies. The effect of pH on the KEC of ZS-9 was tested in different media buffered to mimic different portions of the human gastrointestinal tract. Rapid K+ uptake was observed within 5 minutes - mainly in the simulated small intestinal and large intestinal fluids, an effect that was sustained for up to 1 hour. If approved, ZS-9 will represent a novel, first-in-class therapy for hyperkalemia with improved capacity, selectivity, and speed for entrapping K+ when compared to currently available options.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The authors have read the journal's policy and have the following competing interests: ZS Pharma, Inc. is the commercial funder of this study. F. Stavros, M. Nuttall, and H. Rasmussen are employees of ZS Pharma Inc. and hold stock or stock options in ZS Pharma, Inc. A. Leon is an employee of ZS Pharma Inc., holds stock or stock options in ZS Pharma, Inc., and is named on two patents held by ZS Pharma Inc. A. Yang is employed by Xelay Acumen, Inc., is a paid consultant to ZS Pharma, Inc., and holds stock options in ZS Pharma, Inc. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Conceived and designed the experiments: AL FS MN AY HR. Performed the experiments: AL MN. Analyzed the data: AL MN FS AY HR. Contributed reagents/materials/analysis tools: AL MN. Wrote the paper: FS AL MN HR AY.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0114686